Abstract
It remains uncertain if diastolic heart failure (DHF) is a distinct HF phenotype or a precursor stage of systolic HF (SHF). The unimodal distribution of left ventricular ejection fraction (LVEF) in HF, depressed LV long-axis shortening in DHF, and progression to eccentric LV remodeling in hypertension favor DHF and SHF as successive stages. These arguments are countered by the bimodal distribution of LVEF after correction for gender, by the preserved LV twist in DHF and by the low incidence of eccentric LV remodeling in hypertension. Clinical features, LV anatomy and histology, cardiomyocyte stiffness, myocardial effects of diabetes, and the response to HF therapy support DHF and SHF as distinct phenotypes. Comparison of the myocardial signal transduction cascades that drive LV remodeling in DHF and SHF may solve the controversy. This review analyzes arguments supporting DHF and SHF as successive stages or distinct phenotypes of the HF syndrome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Owan TE, Hodge DO, Herges RM, et al.: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Eng J Med 2006, 355:251–259
De Keulenaer GW, Brutsaert DL: The heart failure spectrum. Time for a phenotype-oriented approach. Circulation 2009, 119:3044–3046.
Sanderson JE: Heart failure with a normal ejection fraction. Heart 2007, 93:155–158.
McMurray J, Pfeffer MA: New therapeutic options in congestive heart failure. Part II. Circulation 2002, 105:2223–2228.
Paulus WJ, Tschöpe C, Sanderson JE, et al.: How to diagnose diastolic heart failure? A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction (HFNEF) by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539–2550.
Cleland JG, Cohen-Solal A, Aguilar JC, et al.: Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002, 360:1631–1639.
Solomon SD, Anavekar N, Skali H, et al.: Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005, 112:3738–3744.
Lee DS, Gona P, Vasan RS, et al.: Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 2009, 119:3070–3077.
Wang J, Nagueh SF: Current perspectives on cardiac function in patients with diastolic heart failure. Circulation 2009, 119:1146–1157.
Drazner MH: The transition from hypertrophy to failure. How certain are we? Circulation 2005, 112:936–938.
Harris KM, Spirito P, Maron MS, et al.: Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216–225.
Lam CS, Roger VL, Rodeheffer RJ, et al.: Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County. Circulation 2007, 115:1982–1990.
Lieb W, Xanthakis V, Sullivan LM, et al.: Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study. Circulation 2009, 119:3085–3092.
Klapholz M, Maurer M, Lowe AM, et al.: Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York heart failure registry. J Am Coll Cardiol 2004, 43:1432–1438.
Bahrami H, Bluemke DA, Kronmal R, et al.: Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study J Am Coll Cardiol 2008, 51:1775–1783.
Zile MR, Gaasch WH, Carroll JD, et al.: Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001, 104:779–782.
Van Heerebeek L, Borbely A, Niessen HW, et al.: Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966–1973.
Van Heerebeek L, Hamdani N, Handoko L, et al.: Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation endproducts and myocyte resting tension. Circulation 2008, 117:43–51.
Ahmed SH, Clark LL, Pennington WR, et al.: Matrix metalloproteinases/tissue inhibitors of metalloproteinases. Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113:2089–2096.
Spinale FG, Coker ML, Heung LJ, et al.: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944–1949.
Polyakova V, Hein S, Kostin S, et al.: Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004, 44:1609–1618.
Borbély A, van der Velden J, Papp Z, et al.: Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005, 111:774–781.
Borbély A, van Heerebeek L, Paulus WJ: Transcriptional and posttranslational modifications of titin: implications for diastole. Circ Res 2009, 104:12–14.
Makarenko I, Opitz CA, Leake MC, et al.: Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res 2004, 95:708–716.
Nagueh SF, Shah G, Wu Y, et al.: Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 2004, 110:155–162.
Krüger M, Kötter S, Grützner A, et al.: Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009, 104:87–94.
Borbély A, Falcao-Pires I, van Heerebeek L, et al.: Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009, 104:780–786.
Anderson MM, Requena JR, Crowley JR, et al.: The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999, 104:103–113.
Yeh CH, Sturgis L, Haidacher J, et al.: Requirement for p38 and p44/p42 mitogen activated protein kinases in RAGEmediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495–1504.
Davis BR, Kostis JB, Simpson LM, et al.: Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2008, 118:2259–2267.
Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456–2467.
Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.
Hernandez AF, Hammill BG, O’Connor CM, et al.: Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. J Am Coll Cardiol 2009, 53:184–192.
Fukata H, Sane DC, Brucks S, Little WC: Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112:357–363.
Kjekshus J, Apetrei E, Barrios V, et al.: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248–2261.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bronzwaer, J.G.F., Paulus, W.J. Diastolic and systolic heart failure: Different stages or distinct phenotypes of the heart failure syndrome?. Curr Heart Fail Rep 6, 281–286 (2009). https://doi.org/10.1007/s11897-009-0038-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-009-0038-0